Patent Linkage

Patent linkage is a regulatory mechanism that ties drug patent protection to the pharmaceutical approval process, creating a system where generic drug approvals cannot issue without first addressing relevant patents: DEFINITION: patent linkage creates a LEGAL CONNECTION between a pharmaceutical patent and the regulatory approval process for a generic version of the patented drug; without patent linkage, a government could approve a generic drug that infringes valid patents — creating immediate infringement and market confusion upon the generic's launch; THE POLICY RATIONALE: pharmaceutical research and development is extraordinarily expensive and time-consuming; patent protection (typically 20 years) is the primary incentive for innovator pharmaceutical companies to invest in drug development; patent linkage ensures that generics cannot enter the market during the patent term without either: receiving a license from the patent holder; successfully challenging the patent's validity or non-infringement; waiting for the patent to expire; WHY LINKAGE IS NEEDED: without linkage, a generic company could obtain regulatory approval, then immediately begin selling the drug — creating instant infringement that would require the patent holder to seek emergency injunctive relief; the patent holder might not know about the generic approval until after the generic was already on market; patent linkage shifts the dispute BEFORE market entry, creating an opportunity to resolve patent questions in advance; THE US MODEL — HATCH-WAXMAN: the Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act, 1984) created the most studied patent linkage system in the world; the Act simultaneously simplified generic entry (abbreviated NDA) while protecting innovator patents (Orange Book, 30-month stay); the Act was intended to balance these interests and accelerate the introduction of generic drugs without destroying the incentive to innovate; INTERNATIONAL SPREAD: the US Hatch-Waxman model influenced similar patent linkage systems in Canada, Australia, China (beginning 2021), Japan, and many countries through bilateral trade agreements (CAFTA, USMCA, Korea-US FTA, etc.); the EU does NOT have mandatory patent linkage — each member country handles the issue differently; TRIPS AGREEMENT: the TRIPS Agreement does not require patent linkage; it is a US policy export promoted through trade agreements.

The FDA's Orange Book (formally, Approved Drug Products with Therapeutic Equivalence Evaluations) is the core of the US patent linkage system: WHAT IS THE ORANGE BOOK: the FDA maintains the Orange Book as a list of approved drug products and the patents protecting them; innovator pharmaceutical companies (NDA holders) must submit patent information to the FDA for listing in the Orange Book; WHICH PATENTS ARE ELIGIBLE FOR ORANGE BOOK LISTING: drug substance patents (covering the active pharmaceutical ingredient); drug product patents (covering formulations, dosage forms, compositions); method of use patents (covering a specific APPROVED therapeutic use); NOT ELIGIBLE: process of manufacture; metabolite (product of metabolism in the body); packaging; intermediate compounds; SUBMITTING PATENTS FOR LISTING: the NDA holder must submit patents to FDA using Form FDA 3542; the patent must claim the approved drug or approved use; FDA does not independently verify that listed patents actually cover the approved drug — FDA relies on the NDA holder's representations; CONSEQUENCE OF ORANGE BOOK LISTING: once a patent is listed, any ANDA (abbreviated new drug application) for a generic version of the drug must address EACH LISTED PATENT; this is done through one of four certifications (Paragraph I, II, III, or IV); PARAGRAPH I (NO PATENT INFORMATION): certifies no patent was filed; PARAGRAPH II (PATENT EXPIRED): certifies the patent has expired; no delay in approval; PARAGRAPH III (PATENT WILL EXPIRE): certifies the patent has not expired and identifies the expiration date; the generic cannot launch until the patent expires; PARAGRAPH IV (PATENT INVALID/NOT INFRINGED): certifies the patent is invalid, unenforceable, or will not be infringed by the generic; this is the most contentious and strategically important certification; ABUSE OF THE ORANGE BOOK: innovator companies have been accused of listing questionable patents (formulation patents; method of use patents for minor variations) to extend exclusivity beyond the core drug patent — a strategy called EVERGREENING; the FDA began facing lawsuits over improper Orange Book listings; under recent FDA policy revisions, the FDA has become more active in delisting patents it finds should not be listed.

A Paragraph IV certification triggers a complex sequence of events under the Hatch-Waxman Act: THE PARAGRAPH IV CERTIFICATION SEQUENCE: STEP 1 — ANDA FILING: the generic drug company files an Abbreviated New Drug Application (ANDA) with the FDA, including a Paragraph IV certification that a specific listed patent is invalid, unenforceable, or not infringed; STEP 2 — NOTICE TO PATENT HOLDER: within 20 days of FDA filing acceptance, the ANDA filer must notify the NDA holder (brand drug company) and all Orange Book patent holders of the Paragraph IV certification; the notice must describe in detail the factual and legal basis for the certification (essentially a notice letter explaining the infringement or invalidity theory); STEP 3 — 45-DAY WINDOW: the NDA holder and patent holder have 45 days from receipt of the Paragraph IV notice to file a patent infringement lawsuit against the ANDA filer; STEP 4 — 30-MONTH AUTOMATIC STAY: if the patent holder files suit within the 45-day window, the FDA AUTOMATICALLY stays approval of the generic ANDA for 30 months from the date the patent holder received the Paragraph IV notice; the FDA cannot approve the generic during this stay period (unless the patent expires, is found invalid, or is found non-infringed before the 30 months expire); STEP 5 — LITIGATION: during the 30-month stay, the parties litigate the patent infringement and validity issues in federal district court (typically Delaware, New Jersey, or SDNY for pharmaceutical cases); WHAT ENDS THE 30-MONTH STAY EARLY: court decision that the patent is invalid or not infringed; court decision that the patent is unenforceable; patent expires; settlement; WHAT HAPPENS AFTER 30 MONTHS: if the litigation is not resolved and the 30-month stay expires, the FDA can approve the generic ANDA (the generic can launch); the patent holder can still seek preliminary injunction to prevent launch; 180-DAY EXCLUSIVITY: the FIRST ANDA filer with a Paragraph IV certification for a given drug AND a specific patent receives 180 days of MARKETING EXCLUSIVITY from the date of first commercial marketing; during this period, the FDA will not approve any other ANDA for the same drug with the same Paragraph IV certification.

The patent linkage system, while designed to protect innovation, has been criticized for enabling anticompetitive strategies that delay generic entry beyond what patent rights justify: EVERGREENING: the practice of filing follow-on patents (formulation, dosage form, method of use, combination) to extend effective exclusivity after core drug patents expire; Orange Book listing of these patents triggers new 30-month stays for each patent challenged; each new patent requires a separate Paragraph IV certification and lawsuit; SERIAL PARAGRAPH IV FILINGS: a generic must certify against EACH Orange Book-listed patent; if a brand drug has 10 listed patents, a generic must file 10 certifications and potentially face 10 separate lawsuits; the cumulative effect can delay generic entry far beyond any single patent's expiration; REVERSE PAYMENT SETTLEMENTS (PAY-FOR-DELAY): in many Hatch-Waxman litigations, the brand company settles with the generic by PAYING the generic company a large sum (the reverse payment — reverse because it goes from the patent plaintiff to the defendant) in exchange for the generic agreeing not to enter the market until the patent expires; the payment is the opposite of what defendants normally pay in patent settlement; FTC v. ACTAVIS, INC. (S.Ct. 2013): the Supreme Court held that reverse payment settlements are subject to antitrust scrutiny under the RULE OF REASON; they are not presumptively legal (because patent settlements are allowed) OR presumptively illegal (because of the anticompetitive effect); courts must analyze whether the settlement unreasonably restrains trade given the specific circumstances; ACTAVIS FACTORS: size of the payment (large unexplained payments suggest the settlement is anticompetitive); duration of the delay; other terms of the settlement; the competitive harm from the settlement; AUTHORIZED GENERICS: brand companies have undermined 180-day exclusivity by launching their own generic version (authorized generic) during the first generic's exclusivity period; not prohibited by statute; reduces the value of the 180-day exclusivity to the first Paragraph IV filer; INTERNATIONAL PATENT LINKAGE CONTROVERSIES: countries implementing patent linkage systems at US urging have faced criticism from public health advocates that linkage delays access to affordable generic medicines, particularly for HIV/AIDS and other diseases in developing countries; TRIPS WAIVER: the 2022 TRIPS waiver agreement (COVID-19) addressed compulsory licensing for vaccines but not the broader patent linkage question.